FORMULATION AND EVALUATION OF
A MATRIX-TYPE TRANSDERMAL
PATCH CONTAINING RIVASTIGMINE
TARTRATE

SWETHA VENNAPOOSA*, DEVAREDDY SANDEEP
Dept. of PHARMACEUTICS, J.K.K MUNIRAJAH MEDICAL RESEARCH FOUNDATION COLLEGE OF
PHARMACY, KOMARAPALAYAM, TAMILNADU, INDIA.
E-MAIL: sandeep1987s@gmail.com

ABSTRACT
Rivastigmine tartrate is an effective reverse cholinesterase inhibitor which binds to both the esteratic and ionic sites of AchE, preventing the enzyme from metabolizing Ach, resulting in higher levels of Ach in the brain. (In Alzheimer’s disease lower levels of Ach leads to impaired memory (dementia) and learning). Thus Rivastigmine tartrate is used in the treatment of mild to moderate dementia of Alzheimer’s disease. Though the drug is rapidly and completely absorbed following oral administration, it shows significant first-pass effect. Its half life is about 1.5 hrs. Gastro intestinal side effects like vomiting, diarrhea, increased acid secretion in stomach and reduced heart rates are reported. The drug Rivastigmine tartrate posses suitable characteristics such as low daily doses (1.5 to 6 mg twice daily), short half-life (1.5 hrs), low molecular weight (400.43 gms) and low melting point (123ºC - 127ºC) which is suitable for incorporation of drug in transdermal drug delivery system. These properties make Rivastigmine tartrate as a model drug for exploring its application as transdermal drug delivery system. To develop a matrix-type transdermal patch containing Rivastigmine tartrate using blend of polymers PVP and EC in the ratios 1:1, 1:3 and 1:5 with 30% Dibutyl phthalate as a plasticizer.

KEY WORDS: Rivastigmine tartarate, Transdermal, Alzheimer’s.

INTRODUCTION
The treatment of an acute disease or a chronic illness has been mostly accomplished by delivery of drugs to patients using various conventional dosage forms; like tablets, capsules, ointments, liquids, aerosols and injectables as drug carriers. This type of drug delivery system is known to provide a prompt release of drug. Therefore, to achieve as well as to maintain the drug concentration within the therapeutically effective range needed for treatment, it is often necessary to take this type of drug delivery systems several times a day. This results in a significant fluctuation of drug levels.

Further the conventional dosage forms used for the control of infection, pain and fertility may cause side effects like nausea, vomiting, gastric irritation and toxicity if they are consumed for long duration.

Continuous I.V. infusion has been recognized as a superior mode of systemic drug delivery that can be tailored to maintain a constant and sustained drug level within a therapeutic concentration range for as long as required for effective treatment. It also provides a means of direct entry into the systemic circulation of drugs that are subjected to hepatic first-pass metabolism and/or suspected of producing gastro-intestinal incompatibility. Unfortunately, such a mode of drug administration entails certain health hazards and therefore necessitates continuous hospitalization during treatment and requires close medical supervision.

To duplicate the benefits of intravenous drug infusion without its potential hazards several technical advancements have been developed. They have resulted in the development of new techniques for drug delivery. These techniques are capable of controlling the rate of drug delivery, sustaining the duration of therapeutic activity and/or targeting the delivery of drug to a particular tissue.

With the concept of delivering drug into the skin for both local effects in dermatology and through the integument for the systemic treatment of disease states, this latter process has been brought into sharp focus in recent years by the efforts of pharmaceutical field to develop transdermal delivery devices to treat motion sickness, angina, hormone deficiency and hypertension.

The novel drug delivery system has brought renaissance into the pharmaceutical industry for controlled drug delivery. The novel drug delivery systems includes transdermal drug delivery system, mucoadhesive drug delivery system, nasal drug delivery system etc.

The transdermal route of drug delivery is gaining accolade with the demonstration of percutaneous absorption of a large number of drugs. This type of drug delivery with the intention of maintaining constant plasma levels, zero order drug input and serves as a constant I.V. infusion. Several transdermal drug delivery
system (TDDS) have recently been developed aiming to achieve the objective of systemic medication through application to the intact skin.

The intensity of interest in the potential bio-medical application of transdermal controlled drug administration is demonstrated in the increasing research activities in a number of health care institutions in the development of various types of transdermal therapeutic systems (TTS) for long term continuous infusion of therapeutic agents including antihypertensives, antianginal, anti-histamine, anti-inflammatory, analgesic drugs etc.

“Transdermal drug delivery systems are adhesive, drug containing devices of defined surface area that deliver a pre-determined amount of drug to the surface of intact skin at a pre-programmed rate. These systems provide drug systemically at a predictable rate and maintain the rate for extended periods of time.

The skin acts as a formidable barrier to the penetration of drugs and other chemicals, it does have certain advantages which make it an alternative route for systemic delivery of drugs. Transdermal drug delivery system involves the passage of substances from the skin surface through the skin layers, into the systemic circulation. The skin has been commonly used as a site for topical administration of drugs, when the skin serves as a port for administration of systemically active drugs. The drug applied topically is distributed following absorption, first into the systemic circulation and then transported to the target tissue, which can be relatively remote from the site of drug application to achieve its therapeutic action,(Chien Yie W. Transdermal drug delivery and delivery systems,1992).1,2,3.

Methods to enhance permeation

1. Chemical means of transdermal penetration enhancement:

In this method various chemicals are used to enhance the permeation across the skin which acts as a tough barrier. Ex: DMSO, menthol, limonene, etc.

Mechanism:

The enhancement in absorption of oil soluble drugs is apparently due to the partial leaching of the epidermal lipids by the chemical enhancers, resulting in the improvement of the skin conditions for wetting and for transepidermal and transfollicular penetration. The miscibility and solution properties of the enhancers used could be responsible for the enhanced transdermal permeation of water-soluble drugs. Some of them alter the composition of the cell content while others effect the cohesiveness between cells and composition of intercellular material or have a direct effect on cell membrane. The composition of intercellular lipids undergo a solid-lipid phase transition at 40°C. It is possible that some penetration enhancers act to disrupt the structure of intercellular lipids and lower the phase transition temperature, thereby increasing the permeability of skin to more polar compounds. To increase the rate of transfer of lipophilic compounds, it is necessary to modify the partitioning characteristics at the stratum corneum viable tissue interface. This may be possible by combining a penetration enhancer with a co-solvent. Some agents can establish a reservoir in stratum corneum, which may facilitate diffusion of drug, when penetrating the epidermis, may carry drug through, by acting as a solvent (Swarna lata soni and Vinod KD,1992). Many of these agents may act by a combination of various effects on the skin while others may be involved in a direct chemical insult on the skin. When the specified lipid film, made up of sebaceous secretion, desquamated cells, sweat and other components, the percutaneous absorption is enhanced slightly. When lipids are removed from the skin as by means of prolonged exposure to polar solvents, however, considerably enhanced absorption of applied materials. It is quite likely that lipid solvents must damage the lipid portion of the membrane before much change in passage through the skin can take place. The existence of a depot or reservoir for topically applied drugs within the stratum corneum was postulated by Malkinson and Furgoson.4,5.

Classification of penetration enhancers:

1. Terpenes (essential oils) : Nerolidol, menthol, 1 8 cineol, limonene, carvone etc.
2. Pyrrolidones : N-methyl-2-pyrrolidone (NMP), azone etc.
3. Fatty acids and esters : Oleic acid, linoleic acid, lauric acid, capric acid etc.
4. Sulfoxides and similar compounds : Dimethyl sulfoxide (DMSO), N,N-dimethyl formamide
5. Alcohols, Glycols, and Glycerides : Ethanol, Propylene glycol, Octyl alcohol etc.
6. Micellaneous enhancers : Phospholipids, Cyclodextrins, Aminoacid derivatives, Enzymes etc.
2. Physical means of penetration enhancement:

The permeation of drugs across the skin is enhanced by physical means like pulsed DC iontophoresis or effect of ultrasounds may have synergistic effect depending upon the current density of pulse current applied and ultrasound intensity time e.g. Ragel’s studied the penetration of tetracycline into the tissues subject to electro and phonphoresis. It was found that tissue levels of tetracycline administered by the use of both electro and phonphoresis were higher than those obtained by the use of either electro or phonphoresis alone6,7,8.

Technologies in the development of TDDS.

A. Membrane moderated systems:

In this, the drug reservoir is totally encapsulated in a shallow compartment molded from a drug impermeable plastic laminate and a rate controlling polymeric membrane. In the drug reservoir compartment, the drug solids are either dispersed in a solid polymer matrix or suspended in an unleachable, viscous liquid medium e.g. silicon fluid. The rate controlling membrane can be micro porous or nonporous polymeric membrane e.g. ethylene vinyl acetate co-polymer on the external surface of the polymeric membrane, a skin layer of drug, compatible hypo allergic adhesive polymer may be applied to achieve an intimate contact of TDDS with skin surface9,10.

Marketed systems

• Transderm-Nitro system for once a day.
• Transderm-Scop system- 3 days medication.
• Catapres- TTS – for weekly treatment.

B. Adhesive diffusion controlled system

It is the simplest version of the membrane moderated drug delivery systems. In this system the drug reservoir is formulated by directly dispersing the drug in an adhesive polymer and then spreading the medicated adhesive casting onto a flat sheet of drug impermeable plastic backing to form thin drug reservoir layer. On the top of the reservoir layer, layers of non-medicated rate controlling adhesive polymer of constant thickness are applied.

Marketed devices.

• Deponit system and Frandol tape

C. Matrix dispersion:

Here the drug reservoir is formed by homogeneously dispersing the drug solids in a hydrophilic or lipophilic polymer matrix and medicated polymer is then molded into disc with defined area and thickness. This is glued onto an occlusive base plate on the surface of the disc, the adhesive polymer is spread along the circumference to form a stripe of adhesive rim around the disc.

D. Micro-reservoir system:

These are considered as combination of reservoir and matrix dispersion type. In this the drug reservoir is formed by first suspending the drug solids in an aqueous solution of water soluble polymer and then dispersing the drug suspension homogenously in lipophilic polymer, by high shear mechanical force to form unleachable microscopic spheres of drug reservoir. This dispersion is stabilized immediately by cross-linking the polymer chains which produces a medicated disc with constant surface area and thickness11,12,13.

AIM AND OBJECTIVE OF THE STUDY

The present work is planned with the following objectives:

- To develop a matrix-type transdermal patch containing Rivastigmine tartrate using blend of polymers PVP and EC in the ratios 1:1, 1:3 and 1:5 with 30% Dibutyl phthalate as a plasticizer.
- To evaluate, the transdermal systems for their physical appearance, moisture content, moisture uptake, thickness, area etc.
- To produce the economical patches for the poor people, by using simple and economical polymers.
- To study In-vitro drug release to ensure drug release was controlled and prolonged over a period of time.
- To lessen the side-effects by using Rivastigmine tartrate containing transdermal patches in comparison to newer analogues in treating Alzheimer’s disease.

METHODOLOGY

Formulation studies

Preparation of backing membrane

The backing membrane was prepared using an aqueous solution of a 6 % w/v of polyvinyl alcohol (PVA) (S.d Fine Chemicals, Boisar, India). Weighed amount of polyvinyl alcohol was added to a definite volume of
warm glass-distilled water and was constantly stirred on a magnetic stirrer at 60°C for few min without formation of bubbles to attain a homogeneous solution. 3 ml of homogeneous solution was then poured into glass cylindrical mold (3.3cm length, 2.3cm internal diameter) to one of the open end which was wrapped by aluminum foil. Smooth uniform, transparent backing membrane was obtained after keeping the mold at 60°C for 6 hours.

Formation of drug matrix over the backing membrane

Blend of polymers PVP and EC were measured in the requisite ratios of 1:1, 1:3 and 1:5 and were dissolved in chloroform in each case [Mukherjee et al.,2006]. A homogeneous solution was made using a magnetic stirrer and a magnetic bead. Rivastigmine tartrate was added to each mixture and stirred for 20 min until a homogeneous suspension was obtained. 3 ml of the homogeneous suspension was then casted on the prepared backing membrane and dried at room temperature for 24 h, which yielded a uniform, flat medicated matrix patch of Rivastigmine tartrate.

Formula:

<table>
<thead>
<tr>
<th>Ingredients</th>
<th>F1(%w/w)</th>
<th>F2 (%w/w)</th>
<th>F3(%w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PVP</td>
<td>2.5</td>
<td>2.5</td>
<td>2.5</td>
</tr>
<tr>
<td>EC</td>
<td>2.5</td>
<td>7.5</td>
<td>12.5</td>
</tr>
<tr>
<td>Dibutyl phthalate</td>
<td>2.85</td>
<td>2.85</td>
<td>12.85</td>
</tr>
<tr>
<td>Drug</td>
<td>1.52</td>
<td>1.52</td>
<td>1.52</td>
</tr>
<tr>
<td>Chloroform</td>
<td>90.63</td>
<td>85.63</td>
<td>70.63</td>
</tr>
</tbody>
</table>

In Vitro studies of Rivastigmine tartrate Patches

In vitro drug release studies:

The release studies were performed using a modified Franz diffusion cell assembly. The backing membrane side of the patches was stuck on a parafilm membrane which was bigger than the actual size of the patch with the help of a water impermeable adhesive. The release liner was removed and the patch was mounted on the diffusion cell with the patch facing the receptor compartment. The receptor compartment was filled with propylene glycol and phosphate buffer (pH 7.4) in ratio of 1:1 and maintained at 37°C. The receptor medium was continuously stirred at 600rpm and 0.5 ml of receptor solution was taken for each sample time point which was immediately replaced with fresh receptor solution. The samples were analyzed using the respective HPLC methods.

RESULTS

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Concentration (µg/ml)</th>
<th>Absorbance(nm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0</td>
<td>0.000</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>0.032</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>0.064</td>
</tr>
<tr>
<td>4</td>
<td>6</td>
<td>0.095</td>
</tr>
<tr>
<td>5</td>
<td>8</td>
<td>0.125</td>
</tr>
</tbody>
</table>

Table 1. Spectrophotometric data for construction of standard graph of Rivastigmine tartrate
Concentration (µg/ml)

Fig 1. standard graph of Rivastigmine tartrate

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Drug name</th>
<th>Melting point (ºC)</th>
<th>Solubility (mg/ml)</th>
<th>Partition coefficient</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Water</td>
<td>Buffer pH 7.4</td>
</tr>
<tr>
<td>1</td>
<td>Rivastigmine tartrate</td>
<td>124 ºC</td>
<td>642.28</td>
<td>743.38</td>
</tr>
</tbody>
</table>

Table -2 Preformulation studies of Rivastigmine tartrate

<table>
<thead>
<tr>
<th>S.No.</th>
<th>Formulation codes</th>
<th>Physical appearance</th>
<th>* Weight (mg)</th>
<th>* Moisture content</th>
<th>**% Moisture uptake capacity (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F1</td>
<td>++</td>
<td>351.45 ± 0.84</td>
<td>4.8±0.20</td>
<td>5.4±0.23</td>
</tr>
<tr>
<td>2</td>
<td>F2</td>
<td>++</td>
<td>351.1 ± 0.73</td>
<td>2.47±0.39</td>
<td>2.95±0.42</td>
</tr>
<tr>
<td>3</td>
<td>F3</td>
<td>++</td>
<td>351.42 ± 0.54</td>
<td>1.56±0.13</td>
<td>1.72±0.17</td>
</tr>
</tbody>
</table>

* → Average of five observations
++ → Satisfactory

Table-3 Evaluation parameters of the transdermal systems

<table>
<thead>
<tr>
<th>Mean diameter of patch (cm) ± SD (n = 10)</th>
<th>Mean area of patch (cm²) ± SD (n = 10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.34 ± 0.032</td>
<td>4.19 ± 0.06</td>
</tr>
</tbody>
</table>

Table -4 Average area of Rivastigmine tartrate patches
### Formulation Code

<table>
<thead>
<tr>
<th>Formulation Code</th>
<th>Mean thickness of whole patch (in mm) ± SD (n = 5)</th>
<th>Mean thickness of backing membrane (in mm) ± SD (n = 5)</th>
<th>Mean thickness of polymer matrix (in mm) ± SD (n = 5)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F1</td>
<td>0.552±0.03</td>
<td>0.259±0.0063</td>
<td>0.293±0.017</td>
</tr>
<tr>
<td>F2</td>
<td>0.573±0.03</td>
<td>0.261±0.0087</td>
<td>0.312±0.014</td>
</tr>
<tr>
<td>F3</td>
<td>0.597±0.02</td>
<td>0.276±0.041</td>
<td>0.321±0.012</td>
</tr>
</tbody>
</table>

Table -5 Thickness of Rivastigmine tartrate transdermal patches

<table>
<thead>
<tr>
<th>Time (Hr)</th>
<th>PVP:EC (1:1) (F1)</th>
<th>PVP:EC (1:3) (F2)</th>
<th>PVP:EC (1:5) (F3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>1</td>
<td>19.73</td>
<td>12.67</td>
<td>8.97</td>
</tr>
<tr>
<td>2</td>
<td>24.97</td>
<td>18.87</td>
<td>14.76</td>
</tr>
<tr>
<td>3</td>
<td>32.42</td>
<td>23.98</td>
<td>19.54</td>
</tr>
<tr>
<td>4</td>
<td>39.88</td>
<td>28.43</td>
<td>22.98</td>
</tr>
<tr>
<td>5</td>
<td>45.63</td>
<td>34.78</td>
<td>27.84</td>
</tr>
<tr>
<td>6</td>
<td>51.45</td>
<td>46.09</td>
<td>35.67</td>
</tr>
<tr>
<td>12</td>
<td>78.05</td>
<td>61.32</td>
<td>54.98</td>
</tr>
<tr>
<td>24</td>
<td>93.65</td>
<td>84.79</td>
<td>79.12</td>
</tr>
<tr>
<td>36</td>
<td>94.77</td>
<td>91.57</td>
<td></td>
</tr>
</tbody>
</table>

Table -6 Invitro drug release studies (Rivastigmine tartrate transdermal patches)

### Conclusion

Rivastigmine tartrate is a reversible cholinesterase inhibitor used for the treatment of mild to moderate dementia of Alzheimer’s disease, which is having a short half-life about 1.5 hours which causes increased frequency of dosing. The matrix films formers PVP and EC in the ratio of 1:1, 1:3 and 1:5 were used here to develop transdermal matrix pattern of Rivastigmine tartrate as these ratios were found to be acceptable in terms of tackiness and consistency by our earlier study (Mukeerjee et al 2006). Further no predominant interaction was detected between the mixture of pure drug and combination of polymers using FT-IR spectroscopy. Various data of the pharmaco technical parameters generated from this study such as thickness, moisture content, moisture uptake, patch area and weight uniformity were found to be favourable to the development of transdermal matrix patches in case of all the three formulations F1, F2, and F3 but F3 was found to be more suitable with slow drug release for the development of transdermal patches.

Invitro drug release studies revealed that the formulation F3 provided sustained release for drug molecules due to increase in amount of EC in the formulation. A more or less similar trend was studied in case of F2 formulation and F1 formulation. When the average rate constant of these 3 formulations were compared it was found that F3 (PVP:EC 1:5) had the slowest release rate of all the formulations studied. Therefore based on the above observations it can be reasonably concluded that PVP-EC (1:5) polymers are better suited over PVP-
EC (1:1 & 1:3) for the development of TDDS of Rivastigmine Tartrate. Hence the formulation F3 (PVP:EC, 1:5) may be used for further pharmokinetic and pharmacodynamic studies in suitable animal models.

REFERENCES

[8] Bradley R. Williams Pharm D, Arlette Nazarians, Pharm D and Mark a Gill Pharm D. A Reversible Cholinesterase Inhibitor ; Department of Pharmacy and Gerontology, University of South Carolina School of Pharmacy, Los Angeles, California., pg 1634-1653